MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available